Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
Open Access
- 20 April 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 1-12
Abstract
Drug discovery and translation are normally based on optimizing efficacy by increasing receptor affinity, functional potency, drug-likeness (rule-of-five compliance) and oral bioavailability. Here we demonstrate that residence time of a compound on its receptor has an overriding influence on efficacy, exemplified for antagonists of inflammatory protein complement C5a that activates immune cells and promotes disease. Three equipotent antagonists (3D53, W54011, JJ47) of inflammatory responses to C5a (3nM) were compared for drug-likeness, receptor affinity and antagonist potency in human macrophages, and anti-inflammatory efficacy in rats. Only the least drug-like antagonist (3D53) maintained potency in cells against higher C5a concentrations and had a much longer duration of action (t1/2 ~ 20 h) than W54011 or JJ47 (t1/2 ~ 1–3 h) in inhibiting macrophage responses. The unusually long residence time of 3D53 on its receptor was mechanistically probed by molecular dynamics simulations, which revealed long-lasting interactions that trap the antagonist within the receptor. Despite negligible oral bioavailability, 3D53 was much more orally efficacious than W54011 or JJ47 in preventing repeated agonist insults to induce rat paw oedema over 24 h. Thus, residence time on a receptor can trump drug-likeness in determining efficacy, even oral efficacy, of pharmacological agents.Keywords
This publication has 46 references indexed in Scilit:
- A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) SignallingBiosensors, 2012
- Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)British Journal of Pharmacology, 2011
- Drug–target residence time: critical information for lead optimizationCurrent Opinion in Chemical Biology, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- The role of the anaphylatoxins in health and diseaseMolecular Immunology, 2009
- QMEAN server for protein model quality estimationNucleic Acids Research, 2009
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- Function, structure and therapeutic potential of complement C5a receptorsBritish Journal of Pharmacology, 2007
- Taking The Time To Study Competitive AntagonismBritish Journal of Pharmacology, 2007